orabase and Lymphoma--B-Cell

Indolent non-Hodgkin's lymphomas (iNHLs) are incurable with standard therapy and are poorly responsive to checkpoint blockade. Although lymphoma cells are efficiently killed by primed T cells, in vivo priming of anti-lymphoma T cells has been elusive. Here, we demonstrate that lymphoma cells can directly prime T cells, but in vivo immunity still requires cross-presentation. To address this, we developed an in situ vaccine (ISV), combining Flt3L, radiotherapy, and a TLR3 agonist, which recruited, antigen-loaded and activated intratumoral, cross-presenting dendritic cells (DCs). ISV induced anti-tumor CD8

Topics: Adult; Aged; Animals; Antigen Presentation; Cancer Vaccines; Carboxymethylcellulose Sodium; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Female; Humans; Immunotherapy, Adoptive; Lymphoma, B-Cell; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Poly I-C; Polylysine; Programmed Cell Death 1 Receptor; Toll-Like Receptor 3; Vaccination